BrainChild Bio Raises $116 Million in Series A Funding
BrainChild Bio, a Seattle-based biotechnology company focusing on pediatric brain tumors, has announced the successful closing of a $116 million Series A funding round. The company specializes in developing CAR-T cell therapies targeting tumors in the central nervous system, with a primary focus on pediatric applications but plans to expand to adult indications.
Investors and Funding Details
The Series A round saw participation from Seattle Children’s and WRF Capital. Although a private family fund and foundation led this financing round, their identities remain undisclosed. This marks a significant step forward for the company as it seeks to advance its clinical programs.
Use of Funds
The newly secured funds will be allocated towards several key initiatives. Primarily, they will support the ILLUMINATE Phase 2 clinical trial for BCB-276, a B7-H3-targeted CAR T cell therapy aimed at treating diffuse intrinsic pontine glioma (DIPG), a rare and aggressive type of pediatric brainstem tumor. Additionally, the funds will help in the development of BCB-214, a triple-targeting CAR T cell therapy set for initial clinical testing in glioblastoma.
Leadership and Vision
Steven Brugger, Chief Executive Officer and Board Director of BrainChild Bio, expressed his commitment to harnessing the potential of CAR-T cell technology to address critical needs in pediatric oncology. "Our path to building BrainChild Bio has led us to secure the support of key investors to advance our mission," Brugger stated.
Focus on Pediatric Oncology
BrainChild Bio is dedicated to advancing treatments for tumors of the central nervous system, utilizing technology licensed from Seattle Children’s. The focus remains on pediatric cases, with ongoing efforts to expand the application of their technology to adult populations.
This funding round represents a significant milestone for BrainChild Bio, as it continues to push forward in the development of innovative therapies for challenging brain cancers.